Published in Anticancer Agents Med Chem on January 01, 2011
Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease. Inflamm Bowel Dis (2012) 1.07
SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. Neoplasia (2014) 0.90
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR. Future Neurol (2012) 0.90
SHP-1 is a target of regorafenib in colorectal cancer. Oncotarget (2014) 0.88
Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer. Neoplasia (2015) 0.87
Shp2 plays an important role in acute cigarette smoke-mediated lung inflammation. J Immunol (2012) 0.87
Astaxanthin treatment reduced oxidative induced pro-inflammatory cytokines secretion in U937: SHP-1 as a novel biological target. Mar Drugs (2012) 0.87
SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma. Oncogene (2015) 0.83
Alterations of cell cycle control proteins SHP‑1/2, p16, CDK4 and cyclin D1 in radioresistant nasopharyngeal carcinoma cells. Mol Med Rep (2014) 0.81
The tyrosine phosphatase SHP-1 regulates hypoxia inducible factor-1α (HIF-1α) protein levels in endothelial cells under hypoxia. PLoS One (2015) 0.79
Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1. Cell Death Dis (2017) 0.78
SHP1-mediated cell cycle redistribution inhibits radiosensitivity of non-small cell lung cancer. Radiat Oncol (2013) 0.78
SHP-1 arrests mouse early embryo development through downregulation of Nanog by dephosphorylation of STAT3. PLoS One (2014) 0.78
Molecular insights for optimizing T cell receptor specificity against cancer. Front Immunol (2013) 0.77
A missense methionine mutation augments catalytic activity but reduces thermal stability in two protein tyrosine phosphatases. Biochem Biophys Res Commun (2016) 0.75
Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells. J Mol Med (Berl) (2017) 0.75
Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells. Mol Oncol (2017) 0.75
Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res (2009) 3.81
A robust and highly efficient immune cell reprogramming system. Cell Stem Cell (2009) 2.06
Long-range epigenetic silencing associates with deregulation of Ikaros targets in colorectal cancer cells. Mol Cancer Res (2011) 0.95
Distinct and specific roles of AKT1 and AKT2 in androgen-sensitive and androgen-independent prostate cancer cells. Cell Signal (2013) 0.90
Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. J Clin Endocrinol Metab (2002) 0.90
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt. Neoplasia (2007) 0.84
Fine-tuning the π-π aromatic interactions in peptides: somatostatin analogues containing mesityl alanine. Angew Chem Int Ed Engl (2011) 0.77
EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway. Carcinogenesis (2012) 0.77
Insights into structure-activity relationships of somatostatin analogs containing mesitylalanine. Molecules (2013) 0.76
SSTR1- and SSTR3-selective somatostatin analogues. Chembiochem (2011) 0.75